Drug news
FDA approves Linzess (Forest/Ironwood) for Chronic Constipation and IBS
The FDA on 30 August 2012 approved Linzess (linaclotide) from Forest Labs and Ironwood Pharma, to treat Chronic Idiopathic Constipation and to treat Irritable Bowel Syndrome with Constipation (IBS-C) in adults. Almirall has the European rights and has filed a marketing application to EMA for Irritable Bowel Syndrome with Constipation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins